2026 CCF Urine Lab 2026 CCF Urine Lab Checklist

Effective April 2025
Rev. 0425

URINE LABORATORY
INFORMATION CHECKLIST

RTI International
National Laboratory Certification Program
3040 East Cornwallis Road
Durham, North Carolina 27713

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond
to, a collection of information unless it displays a currently valid OMB control number. The OMB control
number for this project is 0930-0158. Public reporting burden for this collection of information is estimated
to average 4 hours per respondent per year, including the time for reviewing instructions, searching existing
data sources, gathering and maintaining the data needed, and completing and reviewing the collection of
information. Send comments regarding this burden estimate or any other aspect of this collection of
information, including suggestions for reducing this burden, to SAMHSA Reports Clearance Officer, 5600
Fishers Lane, Room 15E57-B, Rockville, Maryland, 20857.

DATE
Rev. No.
December 12,
2018
Rev. 1218
January 1, 2020
Rev. 0120
April 1, 2025
Rev. 0425

CHANGE
Revisions to the urine laboratory information
checklist are documented in separate document:
Summary of Changes December 2018, NLCP Manual for Urine
Laboratories
Revisions made to the urine laboratory
information checklist for consistency with the oral
fluid laboratory information checklist
Revisions to the urine laboratory information
checklist are documented in separate document:
Summary of Changes -April 1, 2025, NLCP
Manual for Urine Laboratories

QUESTION NO.

multiple
sections
multiple
sections
multiple
sections

NATIONAL LABORATORY CERTIFICATION PROGRAM
URINE LABORATORY CHECKLIST
Table of Contents
I. URINE LABORATORY INFORMATION CHECKLIST
Page
A.

Instructions for the Laboratory

A-1

B.

Laboratory Information

B-1

C.

Laboratory Procedures

C-1

Urine, Laboratory

April 2025

I.

URINE LABORATORY INFORMATION CHECKLIST

A.

INSTRUCTIONS FOR THE LABORATORY

Pre-inspection Materials
Before each scheduled inspection, the NLCP sends instructions to the laboratory listing
the required pre-inspection materials with due dates for provision. The required
materials depend on the inspection type (e.g., initial inspection, maintenance inspection,
records audit, special inspection). The following describes some items that may be
required.
1. NLCP Urine Laboratory Information Checklist (Sections B and C)
The laboratory provides up-to-date information to the NLCP on its drug testing
operation (i.e., staffing, facility, and procedures) using the NLCP Urine Laboratory
Information Checklist (Sections B and C). The information is maintained in NLCP
records and is verified by the inspection team (i.e., inspectors, records auditors) at
each NLCP inspection.
2. Laboratory Operation Schedule/Inspection Schedule
The laboratory provides a schedule of its operations specific for urine to the NLCP,
listing the days and hours for various processes (e.g., receiving, accessioning, initial
testing, confirmation aliquoting, confirmatory drug test sample
preparation/extractions, certification). Using this schedule, NLCP staff prepare a
tentative schedule for the inspection team. To adequately assess operations on
every shift, inspectors will periodically inspect processes that occur during off-shifts.
The lead inspector determines the final schedule for the inspection team at most
NLCP inspections. The lead auditor determines the final schedule for a records
audit. Inspectors should note any changes to the schedule in their checklist
submission.
3. Key Staff Interview List/Staff Hours and Duties
The laboratory provides a list of key staff, their job titles, and work schedules to the
NLCP before each inspection (i.e., Staff Interview list for a maintenance inspection,
Staff Hours and Duties list for a records audit). The laboratory must identify staff “in
training” for a key role. Laboratories certified for both urine and oral fluid testing must
mark the lists to indicate whether staff work with one or both matrices.
NLCP staff select individuals from the Staff Interview list to be interviewed at the
inspection and return the list to the laboratory, instructing the laboratory to ensure
that the selected individuals are available for interview during the inspection. In
addition to interacting with laboratory staff during the course of the inspection, the
inspection team conducts formal interviews (i.e., 10 – 15 minutes each) with each
Urine, Laboratory

A-1

April 2025

selected staff member individually to evaluate their knowledge and ability to fulfill job
duties.
There are no formal staff interviews during an audit. The Staff Hours and Duties list
is provided to the audit team for reference.
4. Laboratory Computers and Information Systems (Section P)
Section P addresses all systems used for regulated drug testing, both internal to the
certified laboratory and external to the certified laboratory (i.e., corporate systems,
external service provider systems). To facilitate the inspection, the NLCP directs the
laboratory to perform a self-assessment using Section P, Laboratory Computers and
Information Systems. Laboratories certified for oral fluid and urine must address
both matrices in their Section P self-assessment. The laboratory will answer Section
P checklist questions and provide explanatory comments (e.g., describe procedures
and records) to support those answers. The laboratory provides the completed
Section P to the inspection team at the beginning of the inspection. If the laboratory
reports any regulated specimens electronically, the inspectors at each maintenance
inspection will review procedures and documentation (e.g., selected specimen
reports) to verify the electronic reporting methods.
5. Floorplan of the Laboratory
The floorplan must clearly identify areas (e.g., accessioning, testing, certification,
reporting), clearly indicate how the areas are secured, and what security devices are
utilized (e.g., which walls are outside walls; which are secured up to the ceiling; the
location and type of security devices, such as magnetic key cards, cipher locks,
padlocks; the location of secured storage areas, such as refrigerators or freezers,
and how they are secured). The laboratory must indicate areas where regulated and
non-regulated testing, processing, and data review occur in the same area, and
where regulated and non-regulated specimens or records are stored in the same
area (i.e., short-term and long-term specimen and records storage areas).
Laboratories certified for oral fluid and urine must identify any areas designated for a
single matrix.
6. Laboratory Data Packages
The laboratory provides data packages to the NLCP: one for a positive specimen
and one for a specimen that was reported as adulterated, substituted, or invalid
based on SVT (i.e., invalid-abnormal pH, invalid-inconsistent creatinine and specific
gravity results, or invalid-possible activity). Laboratories certified for
oral fluid and urine must submit data packages for both urine and oral fluid. These
data packages should contain all chain of custody forms, worksheets, initial drug test
data, screening/differential specimen validity test data, initial specimen validity test
data, confirmatory specimen validity test data, confirmatory drug test data, and
reports pertaining to the specimen. The program-required format for data packages
is described in Section R of the NLCP Manual for Urine Laboratories. These must be
Urine, Laboratory

A-2

April 2025

recent specimens, processed since the last NLCP inspection using the laboratory’s
current procedures. If the laboratory did not report any specimens as specified
during this timeframe, the laboratory may submit a data package for an NLCP PT
sample reported as described above. The laboratory must provide test data for all
samples in the confirmatory drug test batch. Note: if the laboratory uses more than
one technology for initial drug tests (e.g., immunoassay, LC-MS/MS) or confirmatory
drug tests (e.g., GC-MS, GC-MS/MS, LC-MS/MS), the laboratory must also provide
drug test batch data and associated documents for a drug positive specimen tested
using each technology.
7. Hotel list
The laboratory provides a list of several hotels/motels located in close proximity to
the laboratory and to the airport. Hotels selected should ensure the safety and
welfare of the inspectors during the inspection. During the inspection, inspectors
should notify the Responsible Person (RP) of alternate hotel suggestions and notify
the NLCP of suggestions after the inspection.
8. Directions
The laboratory provides a clear, precise map with directions describing the routes
from the airport to the hotels and from the hotels to the laboratory.
Non-Negative Specimen List (NNSL)
Prior to each NLCP inspection that includes a records audit, the NLCP notifies the
laboratory of the specified audit period (e.g., depending on laboratory category, this will
be the three-month or the six-month period ending one month prior to the month of the
inspection). The laboratory is required to identify all regulated urine specimens reported
during that time period as positive, adulterated, substituted, invalid, rejected,
reconfirmed, or failed to reconfirm. In addition, the laboratory must identify all
specimens received for testing from an Instrumented Initial Test Facility (IITF), including
specimens reported as negative. The laboratory must submit to the NLCP a list of these
specimens, with specific information for each specimen. The laboratory also provides a
monthly summary for the records audit period listing the numbers of regulated
specimens reported as positive, adulterated, substituted, invalid, negative, rejected,
reconfirmed, or failed to reconfirm.
The NLCP provides instructions for the NNSL to the laboratory prior to the inspection.
These instructions include, but are not limited to, the following:
1. Format for NNSL spreadsheet
2. NNSL categories:

Urine, Laboratory

A-3

April 2025

•

The laboratory will provide information concerning results reported for the NNSL
categories as outlined in the “NNSL Requirements” document posted on the
NLCP website.

•

If the laboratory has tested a regulated specimen for an additional Schedule I or
II drug upon request of a federal agency and reported the specimen as positive
(i.e., drug present at or above the cutoff used for the test), the laboratory must
submit a separate NNSL sheet for that drug.

•

If no specimen is identified for a specific category, the laboratory must submit
that sheet indicating “None.”

3. Urine specimens to be included on the NNSL:
•

Specimens reported positive, adulterated, substituted, invalid, rejected,
reconfirmed, and failed to reconfirm.

•

Specimens received for testing from an IITF, including those reported negative.

•

The laboratory must not include known NLCP PT samples.

4. Requirements for records assembly:
The NLCP selects specimens from the submitted NNSL for review during the
inspection and provides the selected list to the laboratory and to the lead auditor.
The laboratory must organize and assemble records for each of the selected
specimens to facilitate their review by the audit team during the inspection. At a
minimum, records must be assembled by NNSL category and in chronological order,
to facilitate their location within labeled folders/boxes. Auditors must be able to
retrieve all records (excluding failed batches) pertaining to a specimen on the
selected NNSL with minimal assistance from laboratory staff.
During the inspection, the inspection team should alert the RP when a record
appears to be missing. The lead auditor and the RP will prepare an inventory of
records for the selected specimens on the NNSL that were not available for review.
The RP must forward the missing records to the NLCP for subsequent review and
follow-up.
Laboratory Preparation Criteria List
Prior to each inspection, the NLCP sends a Laboratory Preparation Criteria List to the
laboratory, listing materials that must be available for the inspection team upon their
arrival at the laboratory. Materials include a copy of the standard operating procedures
(SOP) manual for each inspection team member at the start of the inspection (e.g.,
access to the laboratory’s electronic versions and retired versions in effect during audit
period), NLCP PT records, personnel files, quality assurance (QA) records, calibrator
and control records, test material records, validation records, a timeline of any changes
Urine, Laboratory

A-4

April 2025

in calibrator or control criteria and acceptance limits during the records audit period, and
documentation of security procedures (e.g., access rosters and visitor logs for each
secured area). Other items may be requested for review prior to or during the
inspection.
All materials should be in the inspectors’ work area before the arrival of the team. The
laboratory must also take steps to ensure the security of these records when they are
unattended during the inspection. All inspectors and auditors should be given access to
the inspectors’ work area (e.g., each given their own key, access card, or code).

Urine, Laboratory

A-5

April 2025

B.

LABORATORY INFORMATION (completed by the laboratory)

B-1.

Name of Laboratory: ____________________________________
Address: _____________________________________________
_____________________________________________________
City, State, ZIP: ________________________________________
Telephone: ( ___ ) _____-________
e-Mail:

B-2.

FAX: ( ___ ) ____ -______

Responsible Person(s)
RP’s name: ___________________________________________
RP’s title: _____________________________________________
RP’s name: ___________________________________________
RP’s title: _____________________________________________
RP’s name: ___________________________________________
RP’s title: _____________________________________________
Alternate Responsible Person(s)
Alt-RP’s name: _________________________________________
Alt-RP’s title: __________________________________________
Alt-RP’s name: _________________________________________
Alt-RP’s title: __________________________________________

B-3.

I certify that the statements and information presented in Sections B and C
are true and correct as of this date. I affirm that the key staff have read and
are familiar with the current version of the NLCP Manual for Urine
Laboratories. I also recognize my responsibility for providing amended
Sections B and C to the inspectors at the beginning of the inspection if
changes are made between the date of this submission and the inspection.

Note:

Any false, fictitious, or fraudulent statements or information presented in sections
B and C or misrepresentations relative thereto may violate Federal Law and could
subject you to prosecution, monetary penalties, or both (Sec 18 U.S.C. 1001; 31
U.S.C. 3801-812).

Signature, Responsible Person

Date

Signature, Responsible Person

Date

Signature, Responsible Person

Date

Urine, Laboratory

B-1

April 2025

B-4.

List the changes made by the laboratory (e.g., new instrumentation, new
or revised analytical procedures, new or revised software) since the last
NLCP inspection, and effective date of each change:
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________

B-5.

Days/hours of operation of the forensic urine drug testing laboratory:
_________days per week; ________hours per day
If < 7 days, indicate the day(s) that the laboratory is routinely not operational:
_____________________________________________________

B-6.

Does the laboratory have a U.S. Drug Enforcement Agency (DEA)
registration?

YES

NO

If YES, for which schedules?
___1 ___2 ___2N ___3 ___3N ___4 ___5
If NO, explain how reference materials containing controlled substances
are acquired:
_____________________________________________________
_____________________________________________________
_____________________________________________________
B-7.

Describe the relevant State licensure requirements for urine forensic
toxicology for the State in which the laboratory is located:
_____________________________________________________
_____________________________________________________
_____________________________________________________

B-8.

List laboratory certifications/licenses:
____ States (List): ________________________________________________
____ CLIA/HCFA1 (List Specialties): __________________________________
____ CAP2 (List Specialties): ________________________________________
____ NLCP (Specify Matrix):__________________________________________
____ Others (Specify):______________________________________________

Clinical Laboratory Improvement Amendments(CLIA)/Health Care Financing Administration (HCFA)
College of American Pathologists (CAP)

1
2

Urine, Laboratory

B-2

April 2025

a.

Are any of the laboratory’s certifications and/or licenses for a
specialty that is not related to workplace drug testing based on the
qualifications of an RP or Alt-RP?
YES

NO

If YES, list each specialty with the department name, location, and the
name of the individual (i.e., RP or Alt-RP). Note: see also Question B-11
below.
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
B-9.

List name, job title, education, and licenses/certifications for the following
key staff:
Note: (1)
(2)

May attach separate sheet listing additional key staff
Indicate (*) individuals new to the positions in the last 6 months
Name

Job Title

Education

License/
Certification

RP(s)

Alt-RP(s)

Certifying
Scientist(s)

Certifying
Technician(s)

Supervisor(s)

Urine, Laboratory

B-3

April 2025

Other Key
Staff

a.

Is licensure and/or certification required for any of the above
positions in the State in which the laboratory is located?

YES

If YES, describe requirements:
_____________________________________________________
_____________________________________________________
_____________________________________________________
B-10. If there is more than one RP, briefly describe how the RPs share the
responsibilities for HHS-certified laboratory operations and procedures
for urine and for any other matrix for which the laboratory is certified,
and for non-regulated workplace drug testing.
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
B-11. If an RP has any technical and administrative responsibilities that are
not related to workplace drug testing (e.g., in another laboratory
department or location), list the RP’s name, department name and
location, the individual’s responsibilities, and the amount of time spent
(hours/week) on those responsibilities.
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
B-12. Describe the administrative relationships that exist for the key staff of the
forensic drug testing laboratory (see B-9 above):
a.

To whom does the RP(s) report? _____________________

b.

Who evaluates the performance of the RP(s)? ___________
________________________________________________

c.

What staff administratively report directly to the RP(s)? ____

Urine, Laboratory

B-4

April 2025

NO

________________________________________________
________________________________________________
________________________________________________
________________________________________________
d.

The RP(s) evaluates the performance of which staff members?
________________________________________________
________________________________________________
________________________________________________
________________________________________________

e.

Which staff members do not report to the RP(s)? _________
________________________________________________
________________________________________________
________________________________________________
________________________________________________

B-13. Does the laboratory test any federal agency specimens for drugs other
than those specified in the HHS Authorized Drug Testing Panel?

YES

NO

If YES, list the drug(s) and answer a and b below:
_____________________________________________________
_____________________________________________________
a.

Does the laboratory have a copy of the HHS waiver for a federal
agency to test the additional drug(s) on a routine basis?

YES

NO

b.

Does the laboratory maintain written authorization from federal
agencies to test the additional drug(s) on a case-by-case basis?

YES

NO

B-14. Does the laboratory perform additional specimen validity testing for urine
specimens (e.g., for a biomarker or for a specific adulterant other than
those required by the Authorized Biomarker Testing Panel)?
YES NO
If YES, list the measurand for each test and answer questions a and b
below:
______________________________________________________
______________________________________________________
a.

Does the laboratory have approval from the NLCP to perform the
test(s)?

YES NO

b.

Does the laboratory perform the tests on all regulated urine
specimens?

YES NO

If b is answered NO, list the conditions or clients for which specimen
validity testing is performed:
______________________________________________________
______________________________________________________
Urine, Laboratory

B-5

April 2025

______________________________________________________
______________________________________________________
B-15. Average number of urine specimens analyzed by the laboratory each day
for drugs of abuse during the six months preceding submission of
Sections B and C (both regulated and non-regulated specimens):
Specify the months_________________________________
Total urine specimens/day ______
How was this number derived? ____________________________
_____________________________________________________
_____________________________________________________
B-16. The total number of individuals who have authorized unescorted access to
the secure forensic drug testing laboratory facility:
______

individuals

The numbers of individuals with authorized unescorted access to secured
laboratory areas, by role:
______ Staff processing or testing workplace drug testing specimens
______ Support personnel (customer service, IT, maintenance)
______ Other. List each additional role/job title: ____________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
B-17. List the total numbers of staff who are trained and routinely perform the following
activities for regulated urine specimens:
Activity
Accessioning
Initial drug testing
Screening/initial specimen validity testing
Confirmatory specimen validity testing
Specimen preparation (e.g., extraction)
Confirmatory drug testing
Certification

Urine, Laboratory

B-6

No. of
Individuals

April 2025

C.

LABORATORY PROCEDURES (completed by the laboratory)

NOTE: Before using an electronic Federal Custody and Control Form (ECCF) system for
regulated specimens, an HHS-certified test facility must submit a detailed plan and proposed
SOPs for the ECCF system to the NLCP for review and authorization and undergo an onsite
inspection. A similar approval process is used for certified test facilities to use a SAMHSARecognized ECCF system.
C-1.

Provide a description of the laboratory's procedures for the following:
Security
• Building
• Department
• Specimens
• Records

Note: (1)
(2)
C-2.

Insert here.
Do not exceed a total of one page.

Provide a description of the laboratory's procedures for the following:
Specimen Receiving/Accessioning
• Receipt of specimen packages, how they are handled (if received outside the
secured forensic laboratory).
• Review of the Federal CCF and each specimen bottle.
• Completing accessioner CCF entries, assembling specimen batch(es), assigning
laboratory accession numbers.
• Handling and resolution of problems with specimen bottles and/or Federal CCFs.
• Location of all temporary storage area(s).

Note: (1)
(2)
C-3.

Insert here.
Do not exceed a total of one page.

Provide a description of the laboratory's procedures for the following:
Aliquoting Procedures
• Aliquoting from the original specimen bottles (i.e., who and where).
• The aliquoting procedure (method, amounts, handling bottles and tubes, labeling)
for initial and confirmatory drug tests, screening/differential specimen validity
tests, and initial and confirmatory specimen validity tests.
• Transfer of aliquots from the individuals performing the aliquoting to those who
will be testing the aliquots.
• Transfer and storage of original specimen bottles after aliquoting is complete.

Urine, Laboratory

C-1

April 2025

Note: (1)
(2)
C-4.

Insert here.
Do not exceed a total of one page.

Provide a description of the laboratory's procedures for the following:
Specimen Accessioning
• Introduction and/or aliquoting of blind controls into the test batches by
accessioning personnel.
• If applicable, preparation and submission of blind samples as donor specimens
from external sources.

Note: (1)
(2)
C-5.

Insert here.
Do not exceed a total of one page.

Provide a description of the laboratory's procedures for the following:
Initial Drug Tests (First and Second Tests)
• Handling and testing of aliquots by laboratory personnel.
• Maintenance of chain of custody and aliquot identity during the testing.
• Location of all temporary storage area(s).

Note: (1)
(2)
C-6.

Insert here.
Do not exceed a total of one page.

Provide a description of the laboratory's procedures for the following:
Initial Drug Tests (First and Second Tests)
• How batches are constituted (e.g., how many specimens are in a batch, whether
a batch is constituted in one session, or specimens are added to the batch
throughout the day, whether regulated and non-regulated specimens are tested
in the same batch).
• The distribution of specimens, calibrators, and controls within each batch.
• The acceptance criteria for calibration and for each control (open and blind) in
each batch and when and by whom these are evaluated and documented.
• The criteria for accepting all donor specimen results or only a partial number of
donor specimens in a batch.
• For alternate initial drug test technologies (as applicable), the criteria for
accepting, re-preparing, or reinjecting a specimen.

Note: (1)
(2)

Urine, Laboratory

Insert here.
Do not exceed a total of one page.

C-2

April 2025

C-7.

Provide the following information for the first and second initial drug tests:
Describe the procedure(s) and acceptance criteria for calibration:
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
Describe the method used to calculate the concentrations/results of
analytes:
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________

C-8.

Provide a description of the laboratory's procedures for the following:
Specimen Validity Tests (Initial, Confirmatory and Screening/Differential)
• Handling and testing of aliquots by laboratory personnel.
• Maintenance of chain of custody and aliquot identity during the testing.
• List additional specimen validity tests (e.g., for a biomarker or for a specific
adulterant in addition to those required by the Authorized Biomarker Testing
Panel).
• For each additional specimen validity test: the decision points and what
constitutes abnormal results.
• Location of all temporary storage area(s)

Note: (1)
(2)
C-9.

Insert here.
Do not exceed a total of one page.

Provide an outline or a legible flowchart that comprehensively describes the
laboratory's Specimen Validity Testing.

Note: (1)
(2)

Insert here.
Do not exceed a total of one page.

a.

List any changes to the specimen validity testing outline/flowchart
during the time period of the NNSL audit, with the effective date of
each change.
_____________________________________________________
_____________________________________________________
_____________________________________________________

Urine, Laboratory

C-3

April 2025

_____________________________________________________
_____________________________________________________
C-10. Provide a description of the laboratory's procedures for the following:
Specimen Validity Tests (Initial, Confirmatory and Screening/Differential)
• How batches are constituted (e.g., whether a batch is constituted in one session,
or specimens are added to the batch throughout the day, whether regulated and
non-regulated specimens are tested in the same batch).
• The distribution of specimens, calibrators, and controls within each batch.
• The acceptance criteria for each control (open and blind) in each batch and when
and by whom these are evaluated and documented.
• The criteria for accepting all donor specimen results or only a partial number of
donor specimens in a batch.

Note: (1)
(2)

Insert here.
Do not exceed a total of one page.

C-11. Provide the following information for the Specimen Validity Tests (i.e., initial,
confirmatory, and screening/differential tests):
Describe the procedures and acceptance criteria for calibration:
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
Describe the method used to calculate the concentrations/responses of
measurands:
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
C-12. Provide a description of the laboratory's procedures for the following:
Confirmatory Drug Tests
• Handling and testing of aliquots by laboratory personnel.
• Maintenance of chain of custody and aliquot identity during the testing.
• Location of all temporary storage area(s)

Urine, Laboratory

C-4

April 2025

Note: (1)
(2)

Insert here.
Do not exceed a total of one page.

C-13. Provide a description of the laboratory's procedures for the following:
Confirmatory Drug Tests
• How batches are constituted (e.g., how many specimens are in a batch, whether
a batch is constituted in one session, or specimens are added to the batch
throughout the day, whether regulated and non-regulated specimens are tested
in the same batch).
• The distribution of the donor specimens, calibrators and controls within each
batch.
• The acceptance criteria for each control (open and blind) in each batch and when
and by whom these are evaluated and documented.
• The criteria for accepting, re-preparing, or reinjecting a specimen.

Note: (1)
(2)

Insert here.
Do not exceed a total of one page.

C-14. Provide the following information for the Confirmatory Drug Tests:
Describe the requirements for calibration including criteria for exclusion of
unsatisfactory calibrators:
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
Describe the method used to calculate the concentrations of analytes
for each calibration procedure used by the laboratory:
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
Describe the procedures used to assess internal standard recovery
(i.e., the sample or samples used to establish the acceptance range
for the batch, any exclusion criteria).
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
Describe the procedures used to calculate ion ratios and assess
acceptability (i.e., the sample or samples used to establish acceptance
Urine, Laboratory

C-5

April 2025

ranges for the batch).
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
C-15. Provide a description of the laboratory's procedures for the following:
Certification/Reporting Procedures
• Review of all calibration and control data.
• Review of chain of custody forms for the specimen and for all aliquots.
• Review of specimen data.
• Documentation and certification of results (i.e., procedures for paper CCFs,
combination electronic/paper CCFs, and digital CCFs, including use of electronic
signatures by certifying technicians and certifying scientists).
• Release/reporting of results.
• Verification of information (e.g., CCF and computer resident results).

Note: (1)
(2)

Insert here.
Do not exceed a total of one page.

C-16. Provide a description of the laboratory’s procedures for the following:
Electronic Reporting Procedures
• Reporting using an ECCF system: ECCF system provider(s) name and address;
ECCF reporting procedures including how ECCF data are secured (e.g., during
transmission and storage); reporting methods; how MROs access completed
ECCFs.
• Web-based reporting: where report data are sent (i.e., website addresses;
location and ownership of servers); file formats; external service provider(s)
name and address (including cloud-based service providers); how report data are
secured (i.e., during transmission and storage); how MROs access reports.
• Release of computer-generated electronic reports (i.e., methods other than
above).

Note: (1)
(2)

Insert here.
Do not exceed a total of one page.

C-17. Provide an example of the laboratory's computer-generated electronic report for
each of the following laboratory results:
•
•
•

Negative
Negative, Dilute
Rejected

Urine, Laboratory

C-6

April 2025

•
•
•
•
•
•
•
•
•
•
•
•

Cocaine Metabolite Positive
6-AM/Codeine/Morphine Positive
Hydrocodone/Hydromorphone Positive
Amphetamine/Methamphetamine Positive
d-Methamphetamine (if applicable)
Invalid Result
Substituted based on Creatinine and Specific Gravity
Substituted based on Biomarker (if applicable)
Adulterated based on pH
Adulterated: Other (if applicable)
Split Specimen: Reconfirmed
Split Specimen: One or More Primary Specimen Results Not Reconfirmed

C-18. Does the laboratory use an off-site computer information system?

YES

NO

If YES,
Address: _____________________________________________
_____________________________________________________
City, State, ZIP: ________________________________________

C-19. Provide a description of the laboratory's procedures for the following:
Disposition of Specimens and Aliquots
• Handling of original specimen bottles and aliquots after testing is completed.
• Procedure for transferring positive, adulterated, substituted, and invalid
specimens to long-term frozen storage.

Note: (1)
(2)

Urine, Laboratory

Insert here.
Do not exceed a total of one page.

C-7

April 2025

Complete the C Tables:
Contact the NLCP for C Tables focused on technologies other than those in the tables.
Table C-1-a-1.

Immunoassay Initial Drug Test Methods and Instruments

Table C-1-a-2.

Alternate Technology Initial Drug Test Methods

Table C-1-a-3.

Initial Drug Test Methods and Instruments – Liquid Chromatography

Table C-1-a-4.

Initial Drug Test Methods and Instruments – Mass Spectrometry

Table C-1-b.

Immunoassay First Initial Drug Test Calibrators and Controls

Table C-1-c.

Immunoassay Second Initial Drug Test Calibrators and Controls

Table C-1-d.

Initial Drug Test Calibrators and Controls – Alternate Technology

Table C-2-a-1.

Initial Specimen Validity Test Methods and Instruments
(continued on Table C-2-a-2 as needed)

Table C-2-b-1.

Confirmatory Specimen Validity Test Methods and Instruments
(continued on Table C-2-b-2 as needed)

Table C-2-c-1.

Screening/Differential Specimen Validity Test Methods and Instruments
(continued on Table C-2-c-2 as needed)

Table C-2-d-1.

Initial Specimen Validity Test Calibrators and Controls
(continued on Table C-2-d-2 as needed)

Table C-2-d-3.

Confirmatory Specimen Validity Test Calibrators and Controls
(continued on Table C-2-d-4 as needed)

Table C-2-d-5.

Screening/Differential Specimen Validity Test Calibrators and Controls

Table C-3-a.

Confirmatory Drug Test Methods

Table C-3-b-1.

Primary Confirmatory Drug Test Methods and Instruments – Gas
Chromatography

Table C-3-b-2.

Alternate Confirmatory Drug Test Methods and Instruments – Gas
Chromatography

Table C-3-b-3.

Primary Confirmatory Drug Test Methods and Instruments – Liquid
Chromatography

Table C-3-b-4.

Alternate Confirmatory Drug Test Methods and Instruments – Liquid
Chromatography

Table C-3-c-1.

Primary Confirmatory Drug Test Methods and Instruments – Mass Spectrometry

Table C-3-c-2.

Alternate Confirmatory Drug Test Methods and Instruments – Mass Spectrometry

Urine, Laboratory

C-8

April 2025

Table C-3-c-3.

Primary Confirmatory Drug Test Methods and Instruments – Tandem Mass
Spectrometry

Table C-3-c-4.

Alternate Confirmatory Drug Test Methods and Instruments – Tandem Mass
Spectrometry

Table C-3-d-1.

Primary Confirmatory Drug Test Calibrators and Controls

Table C-3-d-2.

Alternate Confirmatory Drug Test Calibrators and Controls

Table C-4-a.

AMPS Enantiomer Test Methods

Table C-4-b.

AMPS Enantiomer Calibrators and Controls

Table C-4-c.

AMPS Enantiomer Result Calculation

Urine, Laboratory

C-9

April 2025